Emergex has secured a ‘state-of-the-art’ research and development (R&D) facility and hired a new chief scientific officer to drive development of its vaccines.
The new research and development facility will be located at Milton Park, Oxfordshire. It will provide the company with its own fully equipped and resourced in-house R&D capabilities, giving it overall internal control of all its vaccine development programmes.
In addition, the biotechnology company has announced the appointment of Dr Phillip Williams as chief scientific officer (CSO), who will lead the company’s R&D operations on site.
A nanotechnology expert, Dr Williams has extensive experience in the field of gold nanoparticle development and has been involved in the production and validation of the world’s first up-scaling methodologies for nanoparticles of this nature.
Storme Moore-Thornicroft, co-founder and chief operating officer of Emergex, commented: “On behalf of the management team, I would like to welcome Phil and our newly appointed team of scientists to Emergex.
“We are looking forward to working together to effectively progress our vaccine candidates through the development pathway. These appointments, along with securing and further enhancing our own operational capability via this new facility, represent a real and significant milestone in the evolution and growth of our business.”
Emergex is initially focussed on creating an internationally accessible, clinical-grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks.
By Anna Smith
Source: Pharma Times
As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.
The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.
At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.
